Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33165-33177

  Patel, Manish R ^a   Jacobson, Blake A ^a   Ji, Yan ^a   Drees, Jeremy ^a   Tang, Shaogeng ^a   Xiong, Kerry ^a   Wang, Hengbing ^a   Prigge, Jennifer E ^a   Dash, Alexander S ^a   Kratzke, Andrea K ^a   Mesev, Emily ^a   Etchison, Ryan ^a   Federspiel, Mark J ^b   Russell, Stephen J ^b   Kratzke, Robert A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Interferon ; NSCLC; Oncolytic virus; Treg; VSV

Indexed keywords

BETA INTERFERON; GREEN FLUORESCENT PROTEIN; JANUS KINASE; RUXOLITINIB; STAT PROTEIN; STAT1 PROTEIN; ONCOLYTIC VIRUS;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL VIABILITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TREATMENT RESPONSE; VESICULOVIRUS; ANIMAL; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; PROCEDURES; VESICULAR STOMATITIS INDIANA VIRUS; VIROLOGY;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-BETA; LUNG NEOPLASMS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 84946075900     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5320     Document Type: Article

References (38)

1. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res. 2013; 161:355-364.
2. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012; 30:658-670.
3. Li Q, Wei YQ, Wen YJ, Zhao X, Tian L, Yang L, Mao YQ, Kan B, Wu Y, Ding ZY, Deng HX, Li J, Luo Y, et al. Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. Int J Cancer. 2004; 112:143-149.
4. Barber GN. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 2004; 17:516-527.
5. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer research. 2009; 69:7713-7720.
6. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. Journal of virology. 2003; 77:8843-8856.
7. Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther. 2010; 21:451-462.
8. Faul EJ, Lyles DS, Schnell MJ. Interferon response and viral evasion by members of the family rhabdoviridae. Viruses. 2009; 1:832-851.
9. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003; 4:263-275.
10. Lee J, Jung HH, Im YH, Kim JH, Park JO, Kim K, Kim WS, Ahn JS, Jung CW, Park YS, Kang WK, Park K. Interferonalpha resistance can be reversed by inhibition of IFN-alphainduced COX-2 expression potentially via STAT1 activation in A549 cells. Oncol Rep. 2006; 15:1541-1549.
11. Balachandran S, Barber GN. PKR in innate immunity, cancer, and viral oncolysis. Methods Mol Biol. 2007; 383:277-301.
12. Balachandran S, Barber GN. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell. 2004; 5:51-65.
13. Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, Baird S, Pearce N, Gronberg S, Wilson B, Prakesh M, Aman A, Isaac M, Mamai A, et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell. 2011; 20:443-456.
14. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol. 2001; 75:3474-3479.
15. Connor JH, Lyles DS. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J Virol. 2002; 76:10177-10187.
16. Malkinson AM, Dwyer-Nield LD, Rice PL, Dinsdale D. Mouse lung epithelial cell lines-tools for the study of differentiation and the neoplastic phenotype. Toxicology. 1997; 123:53-100.
17. Naik S, Nace R, Barber GN, Russell SJ. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther. 2012; 19:443-450.
18. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer research. 2007; 67:2840-2848.
19. Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther. 2011; 19:140-149.
20. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol. 2012; 188:1592-1599.
21. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchroo VK, Khoury SJ. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol. 2007; 179:5228-5237.
22. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. 1999; 162:3256-3262.
23. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol. 2005; 174:4465-4469.
24. Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol. 2002; 169:6842-6849.
25. Rizvi N, Garon EB, Patnaik A, Gandhi L, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting. 2014; 2.
26. Rizvi N, Chow L.Q, Dirix L.Y, Gettinger S.N, Gordon M.S. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting. 2014.
27. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. The Lancet Oncology. 2015; 16:257-265.
28. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 372:2018-28.
29. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20:5064-5074.
30. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science translational medicine. 2014; 6:22ra232.
31. Li Q, Tainsky MA. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One. 2011; 6:e28683.
32. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. Pharmacogenomics of interferonbeta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One. 2008; 3:e1927.
33. Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ. Vesiculovirus neutralization by natural IgM and complement. J Virol. 2014; 88:6148-6157.
34. Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ, Dispenzieri A, Russell SJ. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther. 2013; 20:255-261.
35. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther. 2007; 15:123-130.
36. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33:2780-8.
37. Hierholzer JCaK R.A. Virus isolation and quantification. San Diego, CA: Academic Press Limited1996.
38. Diallo JS, Vaha-Koskela M, Le Boeuf F, Bell J. Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. Methods Mol Biol. 2012; 797:127-140.